cjc 1295 ipamorelin synergy gh release multiple Peptide therapy designed to help your body do what it was built to do — recover, repair, and perform. CJC-1295 and support the body's natural growth-hormone under physician supervision, helping CJC-1295 is one of the

The rationale for stacking the two is that they push GH release through two different pathways GHRH and ghrelin so the pulse should be bigger and more natural-feeling than either compound alone

1998 (PMID 9849822) characterized ipamorelin as the first selective GHS without cortisol/prolactin elevation in rat and swine models

Evidence based recommendations suggest selecting compounds based on specific research objectives not broad applications

By enhancing lipolysis, Ipamorelin aids in the utilization of fat stores for energy, potentially leading to reductions in body fat percentage

Our customer care team are skincare and product experts and can guide you to the best skin of your life.

Regulatory and compounding status All four compounds share a broadly similar regulatory landscape in the United States as of 2026: None are FDA-approved as finished drug products for therapeutic use All are classified as WADA S2 prohibited substances year-round All four have 503A compounding status of Under Review, meaning the FDA Pharmacy Compounding Advisory Committee (PCAC) has nominated them for evaluation but final category assignments (Category 1 permitted for compounding